deucravacitinib + mycophenolate mofetil

**deucravacitinib + mycophenolate mofetil** is a combination of two pharmaceutical agents. Deucravacitinib (BMS-986165) is a highly selective, oral allosteric inhibitor of tyrosine kinase 2 (TYK2), developed by Bristol Myers Squibb, that modulates the immune response by inhibiting IL-12, IL-23, and type I interferon signaling pathways involved in autoimmune and inflammatory diseases[1][3][7]. It is indicated primarily for moderate-to-severe plaque psoriasis, with ongoing research in a range of other immune-mediated conditions[3][7]. Mycophenolate mofetil is an oral immunosuppressant prodrug whose active form inhibits inosine monophosphate dehydrogenase, blocking de novo purine synthesis and thus lymphocyte proliferation; it is used to prevent organ rejection and in various autoimmune diseases. The combination of deucravacitinib and mycophenolate mofetil is investigational, with limited published clinical data on the specific combination; both medications are used to target aberrant immune activity, offering complementary mechanisms in immunomodulation.

Other names

deucravacitinib + mycophenolate mofetil